ResultsIQ

ResultsIQ › Latest results › Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited Q2 FY27 earnings call summary

NSE: ONESOURCE · BSE: 544292

Earnings call of 27 Oct 2026, summarised by AI from the filing.

OneSource reaffirmed FY28 guidance of $400 million revenue and $160 million EBITDA after Q2 FY27 revenue of more than ₹5 billion, up 37% year-on-year.

Key takeaways

  1. FY28 guidance Reaffirmed at $400 million revenue and $160 million EBITDA, on all 3 DDC lines being available for FY28.
  2. Line 2 Second cartridge line operational since September, doubling sterile production days after a delay of about 6 months.
  3. Semaglutide Hikma launched the first generic semaglutide in Saudi Arabia and Dr. Reddy's API supply has commenced.
  4. Line 3 timing Line 3 qualification is lengthy; start targeted Q4 FY27 but commercialisation may slip to start of FY28.

Original filing on BSE

Onesource Specialty Pharma Limited H1 FY27 results

As filed: Revenue ₹961 cr, EBITDA ₹273 cr, PAT ₹137 cr, EBITDA margin 28.4%.

Not scored. No result for the same half-year last year.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹449 cr (+37% year on year), EBITDA ₹123 cr (+39% year on year), PAT ₹25.0 cr, EBITDA margin 27.5% (+25 bps). Score 77 of 100, Above trend. EBITDA margin rose 25 bps year on year. Tax rate -23%. Not enough history for a trend yet: scored on growth alone. Share price after the results: −7.2% in 28 days (Nifty 500: +2.7%).
  • Q4 FY26: Revenue ₹428 cr (+1% year on year), EBITDA ₹91.9 cr (−49% year on year), PAT ₹4.6 cr (−100% year on year), EBITDA margin 21.5% (−1,000 bps). Score 9 of 100, Below trend. EBITDA margin fell 1000 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −9.9% in 30 days (Nifty 500: +1.0%).
  • Q3 FY26: Revenue ₹290 cr (−26% year on year), EBITDA ₹17.3 cr (−88% year on year), PAT −₹88.7 cr, EBITDA margin 6.0% (−1,000 bps). Score 0 of 100, Below trend. EBITDA margin fell 1000 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 23% from last quarter. Share price after the results: −12.5% in 28 days (Nifty 500: +3.0%).
  • Q2 FY26: Revenue ₹376 cr (+300% year on year), EBITDA ₹107 cr, PAT ₹10.0 cr, EBITDA margin 28.5% (+1,000 bps). Score 88 of 100, Above trend. EBITDA margin rose 1000 bps year on year. Other income 50% of PBT. Tax rate -83%. Not enough history for a trend yet: scored on growth alone. Share price after the results: −5.6% in 30 days (Nifty 500: −0.6%).
  • Q1 FY26: Revenue ₹321 cr, EBITDA ₹80.0 cr, PAT ₹25.0 cr, EBITDA margin 24.9%. Not scored. No result for the same quarter last year. Share price after the results: −1.0% in 30 days (Nifty 500: 0.0%).
  • Q4 FY25: Revenue ₹477 cr, EBITDA ₹237 cr, PAT ₹174 cr, EBITDA margin 49.7%. Not scored. No result for the same quarter last year. Share price after the results: +17.5% in 30 days (Nifty 500: +2.8%).
  • Q3 FY25: Revenue ₹337 cr, EBITDA ₹101 cr, PAT −₹73.0 cr, EBITDA margin 30.0%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Onesource Specialty Pharma Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.